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AQUEOUS METHOD FOR MAKING
MAGNETIC IRON OXIDE NANOPARTICLES

for polymer-coated iron oxide nanorod will expedite their use
in applications from magnetic sensors, devices and nanocomposites with magnetic and catalytic properties.
Iron oxide based magnetic nanoparticles have been widely
used in a variety of biomedical applications such as magnetic
separation, magnetic resonance imaging, hyperthermia, magnetically-guided drug delivery, tissue repair, and molecular
diagnostics. For most applications, a polymeric coating is
needed to improve the nanoparticles' aqueous stability, biocompatibility and conjugation properties. Typically, dextrancoated iron oxide nanoparticles have been successfully used
as magnetic resonance imaging (MRI) contrast agent, due to
their strong ability to dephase water protons in surrounding
tissue, which results in a decrease in the MRI signal. In
addition, the dextran coating can be crosslinked and functionalized with amino groups to facilitate the conjugation of
targeting ligands for MRI and in vitro diagnostics applications. Current synthetic procedures for dextran-coated iron
oxide nanoparticles involve the formation of the iron oxide
core in the presence of dextran, as stabilizer and capping
agent, in an alkaline solution. Under these in situ conditions,
the nature, quality and amount of the polymer modulate the
nucleation, growth and size of the newly formed iron oxide
nanocrystal. A common characteristic of most reported in situ
dextran-coated iron oxide nanoparticles synthetic procedures
is the formation of nanoparticles with a spherical iron oxide
core. Research efforts have been geared towards the production of small, uniform and highly dispersed spherical nanocrystals. Only recently, has the importance of the nanoparticles' shape been recognized, in particular one dimensional
(1-D) structures such as nanorods and nanotubes, because
they exhibit unique properties that are different from their
corresponding zero dimensional counterparts (0-D or spherical nanocrystals ). Particularly in the case of iron oxide, 1-D
nanorods have been found to exhibit interesting magnetic
properties due to their shape anisotropy, such as higher blocking temperatures and larger magnetization coercivity, compared to their 0-D counterparts. However, their wide application in biomedical research has been hampered by difficult
and non-reproducible synthetic procedures, use of toxic
reagents and poor yields. For instance, current methods for
making iron oxide nanorods involve hydrothermal, sol-gel
and high temperature procedures, among others. Therefore, a
water-based synthetic procedure for iron oxide nanorods that
is simple, economical, low temperature and high yield would
be in high demand. In particular, synthetic methods that yield
water soluble and stable polymer-coated nanorods would be
ideal for studies geared towards the development of magnetic
biosensors and magnetic devices.
For these reasons, we surmised it would also be advantageous to develop a new, facile, reproducible and low cost
method to synthesize iron oxide nanoparticles for in vitro
applications. In particular, a simple synthetic method that
yields larger nanoparticles (100-500 nm) with a unique crysta! shape and enhanced magnetic relaxation (high R2 and Rl)
would be helpful in studying the effect of shape and size on
the sensitivity of the MRS assay.
To our understanding, it has not yet been reported what
effect larger nanoparticles (100 to 500 nm) would have on the
sensitivity of the magnetic relaxation assay. It has always
been hypothesized that the target induced self assembly of
large nanoparticles would result in nanoparticles clusters too
big that they would settle down (precipitate) and therefore
would render the system useless. However, if these nanoparticles contain a large iron oxide crystal with a high magnetic
relaxation (high R2), a lower amount of nanoparticles would
be required to achieve a detectable T2 signal (MRI signal). In

CROSS-REFERENCE TO RELATED
APPLICATIONS
This is a continuation application of U.S. patent application Ser. No. 13/855,706 filed on Apr. 2, 2013, which is a
continuation application of U.S. patent application Ser. No.
12/174,169 filed on Jul. 16, 2008, which claims priority from
U.S. provisional patent application No. 60/949,945 filed on
Jul. 16 2007, each of which is incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
This invention was made with govermnent support under
National Institutes of Health grant number KOi CAlOl 781.
The government has certain rights in the invention.
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FIELD OF THE INVENTION
The present invention relates to the field ofbiosensors and,
more particularly to a method of making magnetic iron oxide
nanoparticles coated with a polymer and functionalized with
a ligand and the nanoparticles made accordingly.

25

BACKGROUND OF THE INVENTION
30

Iron oxide based magnetic nanocrystals have been widely
used in a variety of biomedical applications such as diagnostic, magnetic resonance imaging (MRI) and in magnetically
guided site specific drug delivery systems. Their use as MRI
contrast agents and as an enhancer in hypothermia (heating of
diseased tissue by application of an RF pulse) has been widely
discussed in the literature. Recently, it has been found that
dextran coated iron oxide nanoparticles, ranging in size from
1 to 100 nm, can be used as magnetic relaxation switches
(MRS) or magnetic relaxation nanosensors (MRnS). When
these nano sensors self assemble in the presence of a molecular target, there is a significant change in the spin spin relaxation time (T2) of neighboring water molecules. This parameter (T2) is a component of the MR signal. The observed
target-induced self assembly of iron oxide based nanoparticles has been used as a sensitive detection method for various targets and reported in the literature.
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SUMMARY OF THE INVENTION
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With the foregoing in mind, the present invention advantageously provides iron oxide nanoparticles that have been
specifically prepared for in vivo studies and for clinical applications, as injectable MRI contrast agents.
Monodisperse, water-soluble dextran-coated iron oxide
nanorods were synthesized using a facile and scalable
method. Our room temperature method involves the mixing
of an acidic solution of iron salts with a basic solution of
ammonium hydroxide to facilitate initial formation of iron
oxide crystals. The stability, cystallinity and shape of these
nanorods depend on the time ofaddition of the dextran as well
its degree of purity. The as-synthesized nanorods exhibit
unique magnetic properties, including superparamagnetic
behavior and high spin-spin water relaxivity (R2). Additionally, they posses enhanced peroxidase activity when compared to those reported in the literature for spherical iron
oxide nanoparticles. Thus, this high yield synthetic method
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such case, the amount of nanoparticles that participate in
cluster formation would be small, resulting in smaller clusters
of magnetic nanoparticles that remain suspended in solution
and do not precipitate out. We hypothesized that having a
lower numberof nanoparticles participating in target-induced
cluster formation would result in a more sensitive assay,
having a lower detection limit.
Accordingly, here we disclose a facile, high-yield, roomtemperature, and water-based synthetic protocol that yields
disperse dextran-coated iron oxide nanorods (DIONrods).
Our synthetic procedure differs from previously reported
methods for dextran-coated iron oxide nanoparticles in that
the dextran is not present during the initial nucleation process.
Instead, the dextran is added at a later stage. This "stepwise"
process, as opposed to the in situ process, allows for the
formation of stable, disperse and highly crystalline superparamagnetic iron oxide nanorods with unique magnetic
properties, such as high blocking temperature and improved
high water relaxivity.

FIG. 6(a) is a time dependent study after addition of! µg of
Antibody against Protein Gin 0.42 µg IO-dextran-protein G
particles; 6(b) depicts another time dependent study where
after addition ofl µg ofAntibody against Protein Gin 0.66 µg
IO-silica-protein G particles; 7(a) is a time dependent study;
after addition of 51.25 CFU MAP in 0.54 µg IO-dextranprotein G particles; control=! µI phosphate buffer, pH 7.4;
and 7(b) is a time dependent study; after addition of 51.25
CFU MAP in 0.82 µg IO-silica-protein G particles; control=411 phosphate buffer, pH 7.4. IO-silica-protein G was
conjugated with antibody specific to MAP and then MAP was
added;
FIG. S(a) hysteresis loops obtained at temperatures SK,
100 K and 200 K; (b) zero field cooled and field cooled
magnetic susceptibilities in an external magnetic field H=200
G; (c) real and (d) imaginary components of ac susceptibility
at different frequencies, the inset of (d) shows the Arrhenius
plot obtained from the imaginary component of susceptibility
measurements; and
FIG. 9(a) dynamic light scattering study ofDIONrods with
ConA; (b) time dependent response in T2 ofDIONrods (200
µ!, 0.002 mg Fe per ml) when treated with 10 µI ConA (1 mg
in 1 ml PBS); (c) FTIR spectraoffreedextranandDIONrods.
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BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the
Office upon request and payment of the necessary fee.
Some of the features, advantages, and benefits of the
present invention having been stated, others will become
apparent as the description proceeds when taken in conjunction with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the invention thereto, and in which:
FIG. 1, according to an embodiment of the present invention, is a TEM image of aminated (a) dextran and (b) silica
coated iron oxide nanoparticles; the TEM images show that
the dextran coated nanoparticles are rod shaped whereas the
silica ones are spherical in nature (Bar=500 nm);
FIG. 2 is a selected area electron diffraction (SAED) image
of aminated (a) dextran and (b) silica coated iron oxide nanoparticles (Bar=5 I/nm); the images show that the dextran
coated particles are more crystalline than silica ones and
consequently showing better magnetic relaxivity;
FIG. 3 shows an XRD pattern of TO nanocrystals wherein
the XRD shows that the peaks matches well with that of
Fe 3 0 4 as reported in literature; both dextran and silica coated
particles show same XRD pattern;
FIG. 4 provides an XPS spectruni of Fe 3 0 4 nanocrystals
where (a) shows the peaks due to Fe2p electrons and (b)
shows that due to 01 s electron; both dextran and silica coated
particles show same XPS pattern; thus, XPS confirms the
formation of Fe 3 0 4 nanocrystals in solution;
FIG. S(a) shows a time dependent study, where after addition of 5 µg avidin in 0.5 µg IO-dextran biotin conjugate; the
control contains 5 µg 0.1 M phosphate buffer, pH 7.4; S(b)
shows a time dependent study after addition of 5 µg avidin in
0.7 µg IO-silica biotin conjugate; the control contains 5 µg 0.1
M phosphate buffer at pH 7.4; S(c) is a plot ofT2 (ms) vs.
Time (min) after addition of 5 µg avidin in 0.5 µg ofboth silica
and dextran coated biotinylated IO particles; S(d) depicts a
dose dependent study where T2 was measured after 1 hr
incubation of the 0.5 µg IO-dextran-biotinylated particles
with avidin at different concentrations; detection limit of
avidin=0.091 µg; S(e) shows a dose dependent study where
T2 was measured after 1 hr incubation of the 0.5 µg IO-silicabiotinylated particles with avidin at different concentrations;
detection limit of avidin=0.071 µg;
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DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENT
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The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or
testing of the present invention, suitable methods and materials are described below. Any publications, patent applications, patents, or other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the
present specification, including any definitions, will control.
In addition, the materials, methods and examples given are
illustrative in nature only and not intended to be limiting.
Accordingly, this invention may be embodied in many different forms and should not be construed as limited to the illustrated embodiments set forth herein. Rather, these illustrated
embodiments are provided so that this disclosure will be
thorough and complete, and will fully convey the scope of the
invention to those skilled in the art. Other features and advantages of the invention will be apparent from the following
detailed description, and from the claims.
FIGS. 1, through 7(b) illustrate various aspects of the
present invention. Herein, we disclose a simple water based
technique forthe synthesis ofhigh quality Fe3 0 4 nanocrystals
having high magnetic relaxivities. The method is based on the
co-precipitation of ferric and ferrous chloride salts in an
acidic environment, with the subsequent growth and morphology of the iron oxide crystal being controlled by addition
of a polymeric capping agent at a specific time. Two different
kinds of capping agents (dextran and silica) have been used in
our experiments, showing that besides stabilization, the capping agents control the morphology and consequently magnetic property of the evolved particles. In our experiments, we
found that rod-shaped particles of approximately 300 nm in
length by about 100 nm in diameter with R2 relaxation of300
mMs-1 were obtained when dextran was used as a capping
agent. On the other hand, spherical nanoparticles of approxi-
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mately 150 run diameter with R2 relaxation of 150 mMs-1
were obtained when a coating of aminated silica was used.
The proper functionalization and bioconjugation of the
nanoparticles with various targeting ligands resulted in robust
nanosensors able to detect a molecular target by magnetic
relaxation with high sensitivity. The high relaxivity of these
particles allow us to do sensing experiments at a very low
concentration of nanoparticles, with improved sensitivity and
without precipitation of the particles because of their size.
Furthermore, the fact that our facile synthetic method yields
different sized particles depending on the polymer used is
novel and can be used to generate multiple sizes and shapes of
particles for further studies.
In our first set of experiments, we optimized the synthetic
protocol, including the order of addition (in situ vs. stepwise), and the time of addition of the dextran polymer. Our
water-based synthetic protocol involves an acid-base reaction
between an acidic solution ofiron salts and a basic solution of
ammonium hydroxide. Upon mixing, the resulting solution
becomes alkaline (pH=9.0), facilitating the formation of iron
oxide nanocrystals. This initial formation of nanocrystals can
occur either in the presence (in situ) or absence (step-wise) of
dextran.
Since most synthetic procedures that afford stable and
monodisperse nanoparticles use an in situ approach, we opted
to try this approach first. In these experiments, a mixture of
iron salts (FeCly6H 2 0 and FeC1 2 .4H 2 0) was dissolved in an
aqueous solution of HCI. A dextran solution was prepared in
aqueous anm10nia solution and placed on a digital vortex
mixer. Finally the resulting iron salt solution was poured at
one time into the ammonia solution of dextran under vigorous
stirring. Following this protocol, we obtained poorly crystalline, spherical nanocrystals of20±5 run in diameter and poor
R2 relaxivity 15 (<1 mMs-1). This poor relaxivity contrasts
with the relaxivity obtained with other published in situ procedures where relaxivity values between 60-100 mMs-1 are
obtained.
We then investigated if a step-wise approach might result in
larger iron oxide nanocrystals and in improved R2 relaxivity.
In this approach, a dextran solution was added at a particular
time after initiating the nucleation of the iron oxide crystals.
In initial optimization experiments, we measured T2 relaxivity (R2) and obtained TEM images of a series of dextran iron
oxide nanoparticles prepared after adding dextran at different
time~ (1, 10, 30 and 60 sec). Following this approach, we
obtamed nanorods where their size, crystallinity and R2
relaxivity improved with time of addition (Table 1). No significant difference was observed between 30 and 60 seconds.
Interestingly, the yield was reduced at 60 sec, based on measurements of the concentration of iron in the solution which
were performed as described. The most optimal pre~aration
was obtained when dextran was added 30 seconds after initiating the iron oxide nucleation, resulting in dextran iron oxide
nanorods (DIONrods) with an R2 of 300 mMs-1.

I. Synthetic Procedure
Synthesis of Aminated Dextran Coated IO Nanoparticles
A mixture ofiron salts containing 0.203 g FeC1 2 .4H 2 0 and
0.488 g FeCl 3 .6H 2 0 in HCl solution (88.7 12 N HCl in 2 ml
water) was added to NH4 0H (830 µl in 15 ml N 2 purged DI
water) and stirred on a digital vortex mixer for 10 sec. Then,
an aqueous solution of dextran (5 gin 10 ml water) was added
to the mixture and stirred for 1 hr. Finally, the entire mixture
was centrifuged for 30 minutes, to pellet large particles, and
the supernatant was collected, filtered and washed several
times with distilled water through an Amicon cell (Millipore
ultrafiltration membrane YM-30 k). This process helps to get
rid of the unbound dextran molecules. The dextran coated
nanoparticle (3 mg, i.e. 3 ml 10 solution containing-I mg Fe
per ml) was then crosslinked by treating with 200 pl epichlorohydrin and 5 ml 0.5 M NaOH and the mixture was stirred
vigorously at room temperature for 8 hrs. Afterwards, the
particles were aminated by mixing 850 W, 30% ammonia and
stirred overnight at RT to get aminated dextran coated 10
particles. The free epichlorohydrin was removed by washing
the solution repeatedly with distilled water using an Amicon
cell.
Synthesis of Aminated Silica Coated IO Nanoparticles:
Amixtureof0.203 gFeCl 2 .4H 2 0 and0.488 gFeCl 3 .6H 0
in HCl solution (88.7 µ112 N HCl in 2 ml water) was poU:ed
into a solution of NH4 0H (830 µl in 15 ml N2 purged DI
water) and stirred on a digital vortex mixer. After 10 sec of
stirring 2680 µl tetraethylorthosilicate, 670 µl 3-(aminopropyl)triethoxysilane and 6180 µl 3-(trihydroxysilyl)propylmethylphosphonate were added to the iron oxide nanoparticle
solution and stirred for 1 hr at 3000 rpm. Then, the solution
w~s ce~t?fuged to remove large particles and washed finally
with d1st1lled water through Ami con cell (Millipore ultrafiltration membrane YM-30 k).
II. Advantages of the Present Method:
1) Facile, cost effective, and green chemistry synthesis that
does not require vigorous experimental conditions.
2) Synthesis does not require the use of toxic reagents and
therefore they are highly biocompatible.
3) Good solubility and stability of resulting particles in
~ater, p~osphate buffer saline and citrate buffer for a long
time penod makes them suitable for biomedical applications.
4) The resulting IO particles can be concentrated using
ultrafiltration devices without inducing agglomeration of the
nanoparticles.
5) The evolved particles are highly magnetic. Therefore
they can be used at a very low concentration for biological
applications.
6) The aminated particles can be conjugated with proteins
and other biomolecules for sensing application.
7) Stable nanoparticles suspension of size range 100-500
run (depending on experimental conditions) can be obtained.
8) Using this protocol, we can obtain iron oxide crystals of
defined size and shape by simply changing the polymer used
as stabilizer/coating. For example, using dextran we favor
formation of rods, while using silica we favor formation of
spheres, under the same general experimental conditions.
9) Other polymers can be used, potentially obtaining other
shapes and sizes of nanoparticles. In particular, biodegradable ~r bi~compatible polymers viz. polyvinyl alcohol, polyacryhc acid, among others can be used in the present method.
10) Resulting nanoparticles can be used for both in vitro
and in vivo applications since synthetic procedure involves
non-toxic materials.
11) Both the silica coating and dextran coating nanoparticles can achieve a strong water relaxation effect. Larger Rl
and R2 are obtained.
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TABLE 1
Effect on T2 relaxivity compared to time of
addition of dextran (8) to the reaction mixture.
60

Time of addition ofDextran (8)
Before adding ammonia
1 sec
10 sec
30 sec
60 sec

<1
50
150

300
300

65
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12) Because of the larger R2 and Rl we can achieve a
detectable MRI signal at low concentration of particles.

TABLE2

III. Characterization
Sample

A. Transmission Electron Microscopy (TEM)
The results of examination of the evolved particles by TEM
are shown in FIG. 1. Shown is the TEM image ofaminated (a)
dextran and (b) silica coated iron oxide nanoparticles. The
TEM images show that the dextran coated nanoparticles are
rod shaped whereas the silica coated nanoparticles are
approximately spherical in nature. (Bar=SOO nm).
FIG. 2 depicts selected area electron diffraction (SAED)
images of aminated (a) dextran and (b) silica coated iron
oxide nanoparticles (Bar=S I/nm). The images show that the
dextran coated particles are more crystalline than silica ones
and consequently showing better magnetic relaxivity.

10-dextranNH2
10-silicaNH2

15

20

C. X-Ray Photoelectron Spectroscopy (XPS)
FIG. 4 provides an XPS spectrum of Fe 3 0 4 nanocrystals
where (a) shows the peaks due to Fe2p electrons and (b)
shows that due to 01 s electron. Both dextran and silica coated
particles show same XPS pattern. XPS confirms the formation ofFe 3 0 4 nanocrystals in solution.

25

30

D. Quantification of Amines
After amination of the resulting nanoparticles, it is important to determine the amount of amine groups present per
gram of iron oxide particles. The quantification of amine
group on the surface ofIO particles is important, as they can
be used to conjugate to a series of targets according to the
amount of amines. The amine groups present per gram of iron
was determined through conjugation of the aminated particles with N-succinimidyl-3-(2-pyridyldithio )propionate
(SPDP). Briefly, SOO µI aminated 10 (-1 mg Fe per ml) was
mixed with 100 µI 0.1 M sodium phosphate buffer (pH 7.4)
and 60 µI 7S mM SPDP in DMSO and kept for 2 hrs. The
unbound nanoparticles and SPDP were removed by passing
the solutions through a Sephadex PD-10 column. Afterwards,
a portion of the IO-SPDP conjugate was treated with 7S µ120
mM 1,4-dithio-DL-threitol (DTT) and stirred for 2 hrs. The
reaction mixture was then passed through Microcon centrifugal filter devices (YM 30) and absorbance of the filtrate was
measured as previously described [Bioconjugate Chem.
1999, 10 186].
NOTE: It has been observed that the aminated IO-silica
and aminated dextran particles have about O.lS2 and 0.106
mmoles of amines present per gram of iron respectively. The
silica coated particles are more easily aminated as the synthesis involves coating materials containing aminating
agents, such as 3-(aminopropyl)triethoxysilane (APTS). On
the other hand, aminated dextran coated particles are synthesized by first crosslinking the dextran coating and then aminating the crosslinked nanoparticle with ammonia. The later
procedure might introduce a limited number of amino groups
to the nanoparticle, as opposed to the silica/APTS protocol.
E. Characteristic Properties of Aminated Dextran and
Silica Coated Iron Oxide Nanoparticles
The characteristics of the aminated dextran and silica
coated iron oxide particles are shown in Table 2, below.

r1
(mM- 1s')

r2
(ml vl - 1s- 1)

r2/rl

mmoles of arnino group per
gram of iron

L-330
B-100
-150

16.80

296

17.61

0.106

12.43

145

11.66

0.152

10

B. X-Ray Diffraction Study (XRD)
FIG. 3 shows the XRD pattern of IO nanocrystals. The
XRD shows that the peaks match well with those ofFe 3 0 4 , as
reported in literature. Both dextran and silica coated particles
show same XRD pattern.

Size
(nm)

35

F. Additional Characterization Studies
Subsequently, we studied the magnetic properties of the
DIONrods. First, hysteresis loops, measured at three different
temperatures (FIG. S(a)), demonstrated a coercivitiy of
SOO±lO G at SK that disappeared at 100 Kand 200 K, which
is typical of superparamagnetic behavior. Zero-field cooled
(ZFC) and Field cooled (FC)--dc susceptibility studies (FIG.
S(b)) show that the ZFC magnetic moment increased as the
temperature increased, reaching a maximum at 28 K (the
blocking temperature, (TB) and then it decreased with further
increase in temperature. In the FC process, above the blocking temperature (TB), the data followed the ZFC curve, but it
deviated from ZFC curve below TB showing a slow increase
in the moment with decreasing temperature. The maximum
found in the ZFC curve (at TB) is where a maximum number
of particles exhibit superparamagnetic behavior. Below TB'
the relaxation times of the particles are longer than the experimental measurement time; hence the particles acquire a
blocked state. In the ac susceptibility, both real and imaginary
components x'(T) and x"(T), at different frequencies ranging
from 1 Hz to 1 kHz exhibited a frequency dependent maximum (FIG. S(c) and FIG. S(d)), which shifted to higher temperatures with increasing frequency. This may be due to either
spin glass or superparamagnetic behavior. To clearly distinguish between these two behaviors, the Mydosh parameter
(<I>) was calculated from the real part of the ac susceptibility
according to the equation:

40

45

50

We used the x'(l Hz) and x'(l kHz) data to calculate <I>,
obtaining a value of0.072. Tm is the temperature corresponding to the observed maximum in x'(l Hz) and llTm is the
expected for superparamagnetic systems is -0.10, which further corroborates that our DIONrods are superparamagnetic.
The particle relaxation time follows the Arrhenius law, given
by:

(-!:.£)

v = voexp ksT
55

60

65

where llE/kB is the energy barrier and K is the experimental
frequency. The data fitted well to a linear relation (inset of
FIG. S(d)) yielding llE/kB-800±10K and T 0 -2xl0- 14 s,
whereas 10- 11 <T 0 <10- 9 sis expected for superparamagnetic
systems. The lower value ofT0 is an indication ofinterparticle
interactions present in the sample. Taken together, these
results show that out DIONrods exhibit superparamagnetic
behavior.
Regarding FIG. 8, panel (a) shows hysteresis loops
obtained at temperatures SK, lOOK and 200K, panel (b)
depicts zero field cooled and field cooled magnetic susceptibilities in an external magnetic field H=200 G, panel (c)

US 9,125,941 B2
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shows real and (d) imaginary components of ac susceptibility
at different frequencies. The inset of FIG. S(d) shows the
Arrhenius plot obtained from the imaginary component of
susceptibility measurements.
Furthermore, we performed experiments to assess the quality and stability of our nanorods. First, the presence of dextran
on nanorod surfaces was confirmed by performing clustering
experiments with Concanavalin-A (ConA). Specifically, the
presence of dextran on nanoparticles can be identified via
ConA-induced nanoparticle clustering, due to the strong
affinity and multivalency of ConA towards carbohydrates,
such as dextran. DLS experiments (FIG. 9(a)) show a timedependent increase in particle size distribution upon ConA
administration, due to formation ofnanoparticle assemblies.
Most importantly, a fast and reproducible change in T2 relaxation time was observed (FIG. 9(b)), not only indicating the
association of dextran with the nanoparticle, but indicating
the feasibility of our DIONrods as magnetic relaxation sensors.
With reference to FIG. 9(a), shown is a dynamic light
scattering study ofDIONrods with ConA; FIG. 9(b) shows
the time dependent response in T2 of DIONrods (200 µl,
0.002 mg Fe per ml) when treated with 10 µl ConA (1 mg in
1 ml PBS); FIG. 9(c) shows FTIR spectra of free dextran and
DIONrods. The FT-IR experiments further confirmed the
presence of characteristic dextran peaks on the DIONrods
preparations. Most importantly, the prepared DIONrods can
be concentrated in PBS by ultrafiltration, obtaining highly
concentrated preparations without nanoparticle precipitation
even upon storage at 4° C. for over twelve months. Taken
together, these results demonstrate the robustness of the dextran coating on the nanorods, making them suitable for biomedical applications.
IV. Applications
A. Conjugation with Biotin:
To conjugate biotin onto the aminated IO nanoparticles, the
nanoparticle solution (1 ml) was incubated with Sulfo-Nhydroxysuccinimide-LC-Biotin (Pierce, 1 mg) for 2 hrs. The
solution was then centrifuged at 13 .2 k rpm for 30 min and the
supernatant was discarded. The pellet was then redispersed in
phosphate buffer (pH 7.4) to obtain biotinylated nanoparticles. The centrifugation and redispersion were repeated
three times to get rid of unbound biotin molecules. The presence of biotin on the surface of nanoparticles was assessed via
biotin-avidin interaction through magnetic relaxation. The
biotin-avidin interaction is used as a model system to prove
the utility of our nanoparticles as magnetic relaxation
switches. The binding of avidin to the biotin of the nanoparticles causes clustering of the nanoparticles with a concomitant decrease in T2 relaxation time. The biotinylated particles
were targeted with avidin and the changes in T2 was measured in a relaxometer at 0 .4 7 T. It has been observed that even
a very low concentration of the biotinylated particles can
sense avidin through magnetic relaxometer.
In that regard, FIG. S(a) shows a time dependent study.
After addition of 5 µg avidin in 0.5 µg IO-dextran biotin
conjugate. The control contains 5 µl 0.1 M phosphate buffer at
pH 7.4. FIG. S(b) shows another time dependent study, this
after addition of 5 µg avidin in 0.7 µg IO-silica-biotin conjugate. The control contains 5 µl 0.1 M phosphate buffer, pH
7.4. FIG. S(c) shows a plot ofT2 (ms) vs. Time (min) after
addition of 5 µg avidin in 0.5 µg of both silica and dextran
coated biotinylated IO particles. NOTE: At this concentration
of iron, aminated silica coated particles show greater sensitivity than the dextran coated ones, as silica coated particles

have more amine groups on their surface. Therefore, they are
more biotinylated and can conjugate with avidin to a greater
extent.
FIG. S(d) presents a dose dependent study where T2 was
measured after 1 hr incubation of the 0.5 µg IO-dextranbiotinylated particles with avidin at different concentrations.
The detection limit of avidin=0.091 µg.
FIG. S(e) shows another dose dependent study where T2
was measured after 1 hr incubation of the 0.5 µg IO-silicabiotinylated particles with avidin at different concentrations.
Detection limit of avidin=0.071 µg. NOTE: Here also, the
silica coated biotinylated 10 particles show better sensitivity
with respect to dextran coated ones for avidin and can detect
the presence of avidin to a lower concentration.
B. Conjugation of Protein G withAminated Nanoparticles
To conjugate IO nanoparticles with protein G at first the
particles are to be dissolved in DMSO to conjugate with
disuccinimidyl suberate (DSS). The DMSO suspensionofthe
IO nanoparticles was obtained by combining 1 ml of aminated nanoparticles with 1 ml isopropanol, mixing well and
spinning down at 13 .2 k rpm for 1 hr. The supernatant was
decanted and the pellet was dissolved completely in 500 µl
DMSO. The suspension was again treated with isopropanol
and spinned down. The centrifugation and redispersion were
repeated three times to get rid of trace amounts of water.
Afterwards the nanoparticle pellets were again redispersed in
500 µl DMSO and to that suspension 5 µl of disuccinimidyl
suberate (DSS, 5.88 mg in 128 µl DMSO) was added. The
mixture was stirred well and allowed to react for 30 mins to
link DSS on the surface of the particles. Then the DSS linked
particles were treated with 1.5 ml isopropanol and mixed
properly. The reaction mixture was centrifuged and pellets
were again dispersed in DMSO. The centrifugation andredispersion was repeated for 3 times to eliminate excess DSS.
Finally, the pellets were redispersed in protein G (Sigma)
solution (1 mg protein G in 1 ml, 200 mM phosphate buffer,
pH 8.0). The mixture was kept for 1 hr at room temperature
and then overnight at 4° C. to obtain the protein G functionalized particles.
The synthesized protein G functionalized nanoparticles
were targeted with an antibody against protein G and the
changes in T2 were measured (FIGS. 6a and 6b). FIG. 6(a)
shows a time dependent study: after addition of 1 µl of antibody against protein Gin 0.42 ug IO-dextran-protein G particles. FIG. 6(b) is a time dependent study, where after addition of 1 µl of antibody against protein Gin 0.66 µg IO-silicaprotein G particles. NOTE: When an antibody specific to
protein G was added to protein G functionalized nanoparti cl es, a concomitant decrease was observed due to clustering
of the particles. The antibody binds to the proteins and causes
clustering with other antibody conjugated particles. Consequently an instantaneous decrease in T2 was observed. The
silica coated protein G functionalized particles show a greater
decrease as compared to dextran coated ones. The presence of
more amines on their surface of silica coated particles made
them more easily bounded to protein G and causes a greater
change in T2 relaxation time when treated with antibody.
C. Detection of Mycobacterium avium Paratuberculosis
(MAP)
To test the capability of our particles in sensing a "real"
target we plarmed to use the newly synthesized protein G
conjugated particles to sense the presence of bacteria in fluid
media. As a model system, we used Mycobacterium avium
paratuberculosis (MAP). A MAP specific magnetic nanosensor was prepared by conjugating an anti-MAP antibody to
protein G-IO nanoparticles.
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Up~n addi~ion

of the bacteria to a solution containing the
bactena-spec1fic nanosensors, a rapid and sensitive detection
of the bacterial target was achieved via changes in T2. This
observation proves that our relatively large iron oxide nanoP.art.icles can be used to detect a molecular target in solution,
s1m1lar to previously reported studies that use smaller nanoparticles in the range of30-50 nm [Perez, J.M., Nat Biotechnol. 2002, 20(8): p. 816-20].
FIG. 7 (a) presents the results of yet another time dependent
study, after addition of 51.25 CFU MAP in 0.54 µg IOdextran-protein G particles. The control=! p.1 phosphate
buffer, pH 7.4. IO-dextran-Protein G was conjugated with an
antibody specific to MAP and then MAP was added. FIG.
7(b) is a time dependent study, showing after addition of
51.25 CFUMAP in0.82 µgIO-silica-proteinGparticles. The
control=! µl phosphate buffer, pH 7.4. IO-silica-protein G
was conjugated with antibody specific to MAP and then MAP
was added.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the inventi on and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.
The invention claimed is:
1. An aqueous method of making polymer coated superparamagnetic nanoparticles, the method comprising:
providing a mixture of iron salts in aqueous hydrochloric
acid;
combining a solution of ammonium hydroxide with the
mixture and stirring for a time sufficient for formation of
a suspension of iron oxide nanoparticles;
ad~ing to the suspension one or more aqueous biocompat1ble polymers thereby coating the nanoparticles with
~olyn_ier, wherein optionally at least one of the polymers
1s ammated;
centrifuging the suspension, rendering a supernatant without large particles;
filtering the supernatant through an ultrafiltration membrane and collecting the filtrate containing the polymer
coated nanoparticles;
crosslinking the polymer coating by treating the nanoparticles with epichlorohydrin and sodium hydroxide while
mixing for up to about eight hours;
aminating any un-aminated crosslinked polymer remaining by treating with ammonia; and
removing free epichlorohydrin from the suspension.
2. The method of claim 1, wherein the iron salts are
selected from FeC1 2 , FeCl 3 , and combinations thereof.
3. The method of claim 1, wherein the biocompatible polymer comprises dextran.

4. The method of claim 1, wherein the biocompatible poly-
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mer comprises silicon.
5. The method of claim 1, wherein the biocompatible polymer is selected from dextran, polyvinyl alcohol, polyacrylic
acid, a silicon-based polymer and combinations thereof.
6. The method of claim 1, wherein the biocompatible polym_er is sel~cted from tetraethylorthosilicate, 3-(aminopropyl)
tnethoxys1lane, 3-(trihydroxysy lily l)propy lmethy lphosphonate and combinations thereof.
. 7. A.suspension of rod-shaped nanoparticles comprising
iron oxide coated with a crosslinked aminated biocompatible
polymer, said nanoparticles having a major dimension and a
minor dimension, and having a relatively high magnetic R2
relaxation.
8. The suspension of claim 7, wherein said iron oxide forms
a superparamagnetic core of the rod-shaped nanoparticles.
9. The suspension of claim 7, wherein said biocompatible
polymer is dextran.
10. The suspension of claim 7, wherein said biocompatible
polymer is selected from dextran, polyvinyl alcohol polyacrylic acid, and combinations thereof.
'
11. The suspension of claim 7, wherein the minor dimension of the rod-shaped nanoparticles is approximately 113 of
the major dimension.
. 12. The suspension of claim 7, wherein the major dimens10n of the rod-shaped nanoparticles is approximately in the
range of 100-500 nm.
13. T.he suspension of claim 7, wherein the relatively high
magnetic R2 relaxation is in the approximate range of 300400 mMs-1.
14. The suspension of claim 7, wherein the rod-shaped
nanoparticles further comprise a ligand conjugated to the
crosslinked aminated dextran.
15. T~e suspension of claim 7, wherein the rod-shaped
nanopart1cles further comprise a protein G ligand conjugated
to the crosslinked aminated dextran.
16. A suspension of superparamagnetic nanoparticles
wherein said nanoparticles comprise a core of iron oxide
coated :-"ith a crosslinked aminated silicon-containing polymer, said nanoparticles having a size of approximately from
100 nm to 500 nm.
17. The suspension of superparamagnetic nanoparticles of
claim. 16, wherein the nanoparticles are approximately
sphencal and the size is a diameter.
18. The suspension of superparamagnetic nanoparticles of
claim 16, wherein said nanoparticles have an R2 relaxation of
approximately 150 mMs- 1.
~9. The suspension of superparamagnetic nanoparticles of
claim 16, further comprising a ligand conjugated to the
crosslinked aminated silicon-containing polymer.
20. The suspension of superparamagnetic nanoparticles of
claim 16, further comprising a protein G ligand conjugated to
the aminated silicon-containing polymer.
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